Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions

Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study

This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.

Study Overview

• Status: Recruiting
• Conditions: Intravenous Lidocaine and Immunity
• Intervention / Treatment: Drug: intravenous lidocaine (IVL); Other: Placebo

Detailed Description

Hypothesis: We hypothesize that the intravenous lidocaine (IVL) versus placebo administered during laparoscopic colorectal surgery will allow for: a reduction in intraoperative remifentanil consumption, an improvement in patients' early rehabilitation after surgery, and an enhancement of the immune profile of our patients through an increase in the balance Th1/Th2 and cellular immunity.

Background: so far, IVL was shown to have several properties: analgesic, anti-inflammatory, and anti-hyperalgesic. Its effects on rehabilitation and pain are still controversial except for abdominal surgery. To date, no study evaluated the impact of IVL in colorectal surgery on intraoperative consumption of remifentanil. Postoperative immune suppression is multifactorial and depends on the surgical traumatism, but also on the doses of opioids given during anesthesia. No study evaluated in colorectal surgery the impact of IVL on postoperative cellular immunity and on the risk of cancer recurrence.

Specific Objectives: primary objective: to reduce by 30% the consumption of remifentanil in the IVL group versus the placebo group; secondary objectives: to evaluate the quality of recovery from anesthesia in the OR (awakening and extubation time), in the PACU and on the wards (pain scores, opioid consumption with patient controlled analgesia (PCA), postoperative nausea and vomiting (PONV), transit recovery time, time in PACU and time in hospital), and to evaluate the postoperative inflammatory parameters and adaptative immune functions (Th1/Th2) until postoperative 48h.

Methods: 60 adult patients ASA 1-3 scheduled for elective laparoscopic colorectal surgery will be included in this randomized controlled trial. Randomisation will be into group Control (C) and Lidocaine (IVL). Anesthesia and monitoring will be standardized and accompanied with the monitoring of the depth of anesthesia (BISpectral index, Medtronic) and the depth of analgesia (NoL index, Medasense LTD, recorded on an observational manner). IVL group will blindly be administered intravenous 1.5 mg/kg lidocaine bolus and then 1.5 mg/kg/h until the end of the surgery as previously described. C group will receive the same amount (ml) of placebo. Statistics: a preliminary analysis (idem group C) showed that the total amount of remifentanil given for this type of surgery was 2481+/-985 mcg (duration 141+/-30Min). Considering that we wish to reduce by 30% the remifentanil consumption in the group IVL, the number of patients to be included per group is 30 (alpha 0.05 and beta 20%).

Significance/Importance: this study will evaluate the impact of IVL on intraoperative consumption of remifentanil but also on immune functions after surgery in order to reduce the risk of cancer recurrence. If this study brings positive results, this will lead to a significant change in clinical practice of anesthesia. This is a pilot study on the immune functions, but this might bring very strong results to ask for future grants on the impact of IVL on cancer recurrence.

Study Design: Prospective, randomized controlled study. Subject Population: Adult patients scheduled to undergo elective laparoscopic colorectal surgery under general anesthesia.

Sample Size: 60 patients will be evaluated in this study. Study Duration: 1 year. Study Center: Maisonneuve-Rosemont Hospital, CIUSSS de l'Est de l'Ile de Montreal, Montreal, Quebec, Canada.

Adverse Events: None expected.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Philippe Richebé, MD PhD; Phone Number: 514-743-6558; Email: philippe.richebe@umontreal.ca
• Study Contact Backup: Name: Nadia Godin, RN; Phone Number: 3193 514-525-3400; Email: ngodin.hmr@ssss.gouv.qc.ca

Study Locations

• Canada
  • Quebec
    • Montréal, Quebec, Canada, H1T2M4
      • Recruiting
      • Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
      • Contact: Philippe Richebe, MD, PhD; Phone Number: 514-743-6558; Email: philippe.richebe@umontreal.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ASA status I, II or III
• Patients older than 18 years
• Colonic surgery
• Classical management of ERAS program patients in our center

Exclusion Criteria:

• Arrhythmia, abnormal electrocardiographic , antiarrhythmic therapy
• Immunosuppressive treatments, corticosteroids or long-term NSAIDs (multiple weekly doses) or during preoperative 48 hours
• conversion intraoperative of a laparoscopic surgical technique to a laparotomy technique
• Pregnant women
• Inability to complete the questions related to this study
• Inability to use hydromorphone postoperative PCA
• Intolerance or allergy to lidocaine, hydromorphone or any other drug that is included in the protocol for perioperative management

Unexpected events leading to the exclusion:

• Difficult unplanned intubation
• Surgical complication requiring aggressive haemodynamic support (vasopressors, inotropes, transfusion)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: intravenous lidocaine (IVL); Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.	Drug: intravenous lidocaine (IVL); lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
Placebo Comparator: Placebo; Will receive the same volume of normal saline for the entire duration of anesthesia.	Other: Placebo; Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine ("IVL") group compared with the control group ("C"). Total consumption of remifentanil in mcg.	Reduction of total intraoperative remifentanil consumption by 30% in the intravenous lidocaine group compared with the control group.	Intra-operative, 5 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the number of remifentanil boluses given intraoperatively (n)	Evaluation of the number of remifentanil boluses given intraoperatively, based on the intraoperative NOL index from T0 which is the time of the incision	T0 to end of surgery, 5 hours
Assessment of total consumption of inhaled anesthetic desflurane in ml	The Dräger Perseus A500 that we have in each anesthesia room offers the opportunity to get the ml of halogenous gas consumed precisely, and our electronic extraction database will allow to have this data in ml per second and the total at the end of surgery	intra-operative
Evaluation of time for extubation	Evaluation of time for extubation after surgery in the operating room	post-operative 1 hour
Evaluation of the hydromorphone dose in mg used in the post-operative care unit (PACU) titration	Evaluation of the hydromorphone dose in mg used as post-operative titration immediately in the recovery room (PACU) to obtain NRS pain scores < 3/10	in recovery room, 3 hours
Evaluation of the nausea and vomiting scores, 0 to 3 scale	Evaluation of the nausea and vomiting scores (0 to 3) for the first 48 hours	48 hours
Evaluation of the length of stay in the recovery room based on the Aldrete scores (Score from 0 to 9)	Evaluation of the length of stay in the recovery room based on the Aldrete scores (time to be ready to leave the recovery room)	in recovery room, 3 hours
total hydromorphone consumption (mg) after PACU, on wards	total hydromorphone consumption (mg given by Patient Controlled Analgesia) on wards for 48 hours	48 hours
Evaluation of the satisfaction of the patient scale 0 to 100 (%)	Evaluation of the satisfaction of the patient as for the management of his pain for 48 hours	48 hours postoperatively
Assessment of total hospital duration of stay in hours	Assessment of total hospital stay in hours	7 days postoperatively
Evaluation of the time in hours required for the emission of a first gas in hours	Evaluation of the time in hours required for the emission of a first gas, a sign of resumption of normal intestinal function	5 days postoperatively
Assessment of rehabilitation scores and cognitive functions	Assessment of rehabilitation scores and cognitive functions at 48h after surgery	2 days
Assessment of cytokines in plasma	Assessment of inflammation parameters by blood sample for 48 hours	48 hours

Collaborators and Investigators

• Sponsor: Ciusss de L'Est de l'Île de Montréal
• Collaborators: Foundation of Anesthesia and Resuscitation of Quebec
• Investigators: Principal Investigator: Philippe Richebé, MD, PhD, CIUSSS Est de l'île de Montréal

Study record dates

Study Major Dates

• Study Start (Actual): April 29, 2019
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): June 1, 2025

Study Registration Dates

• First Submitted: January 19, 2018
• First Submitted That Met QC Criteria: January 24, 2018
• First Posted (Actual): January 25, 2018

Study Record Updates

• Last Update Posted (Actual): October 18, 2023
• Last Update Submitted That Met QC Criteria: October 17, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: colorectal cancer; anesthesia; lidocaine; inflammation; cytokine; laparoscopy surgery; post-operative immunosuppression
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: 2017-1066

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No